Association between osteopontin promoter variants and diastolic dysfunction in hypertensive heart in the Japanese

Hiroyuki Nakayama1, Hiromi Nagai, Kyotaka Matsumoto

  • 1Department of Clinical Pharmacology and Pharmacogenomics, Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan.

Insights

The -156del/G polymorphism in the Osteopontin (OPN) promoter is linked to worse diastolic dysfunction in hypertensive patients. This suggests OPN plays a role in hypertension-related heart problems.

Area of Science:

  • Cardiology
  • Genetics
  • Molecular Biology

Background:

  • Heart failure with preserved ejection fraction (HFpEF) is a growing health concern.
  • Diastolic dysfunction, often linked to hypertension, is a key factor in HFpEF development.
  • Osteopontin (OPN), a protein mediating fibrosis, is implicated in systolic dysfunction but its role in diastolic dysfunction is unclear.

Purpose of the Study:

  • To investigate the association between the Osteopontin (-156del/G) promoter polymorphism and diastolic dysfunction in hypertensive individuals.
  • To determine if OPN genetic variants influence left ventricular diastolic function in hypertension.

Main Methods:

  • Genotyping of hypertensive patients for the Osteopontin (-156del/G) promoter polymorphism using genomic sequencing.
  • Assessment of left ventricular diastolic function via echocardiography, measuring the early to atrial filling (E/A) ratio.
  • Statistical analysis including multiple linear regression to identify independent factors.

Main Results:

  • Patients with the -156G allele of the OPN promoter exhibited a lower E/A ratio, indicating impaired diastolic function, compared to those with the -156del/del genotype.
  • This association was particularly significant in hypertensive patients with diabetes mellitus.
  • The -156G allele was identified as an independent predictor of reduced E/A ratio.

Conclusions:

  • The -156del/G genetic variants in the Osteopontin promoter are associated with decreased left ventricular diastolic function in hypertensive patients.
  • These findings suggest a functional role for Osteopontin in the pathogenesis of diastolic dysfunction within hypertensive hearts.

Related Concept Videos

Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
Hypertension III: Clinical Manifestations and Diagnostic Studies01:30

Hypertension III: Clinical Manifestations and Diagnostic Studies

Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
Hypertension and Regulation of Blood Pressure01:18

Hypertension and Regulation of Blood Pressure

Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
Hormonal Regulation of Blood Pressure01:17

Hormonal Regulation of Blood Pressure

Endocrinal or hormonal intervention in the cardiovascular system is predominantly exerted by the catecholamines - epinephrine and norepinephrine, as well as a slew of hormones that interact with renal function to modulate blood volume.
Epinephrine and Norepinephrine
The adrenal medulla releases epinephrine and norepinephrine, catecholamines that enhance and extend the sympathetic or "fight or flight" physiological response. These hormones escalate heart rate and the force of contraction while...